Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells

Muscle and Nerve

Volumn 37, Issue 2, 2008, Pages 190-195

  Argilés, Josep M ^a   Figueras, Maite ^a   Ametller, Elisabet ^a   Fuster, Gemma ^a   Olivan, Mireia ^a   De Oliveira, Cibely Cristine Fontes ^a   López Soriano, Francisco J ^a   Isfort, Robert J ^b   Busquets, Sílvia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Adipose tissue; Cachexia; Corticotropin releasing factor; Metastases; Muscle; Tumor

Indexed keywords

CORTICOTROPIN RELEASING FACTOR DERIVATIVE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; PG 873637; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACHEXIA; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFECT; GASTROCNEMIUS MUSCLE; LEWIS CARCINOMA; METASTASIS; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SKELETAL MUSCLE; SOLEUS MUSCLE; TIBIALIS POSTERIOR MUSCLE; TUMOR GROWTH; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; CACHEXIA; CARCINOMA, LEWIS LUNG; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; NEOPLASM TRANSPLANTATION; ORGAN SIZE; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 38949151848     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20899     Document Type: Article

References (37)

1. Argilés JM, Almendro V, Busquets S, López-Soriano FJ. The pharmacological treatment of cachexia. Curr Drug Targets 2004;5:265-277.
2. Argilés JM, Alvarez B, López-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev 1997;17:477-498.
3. Argilés JM, García-Martínez C, Llovera M, López-Soriano FJ. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 2003;6:401-406.
4. Boorse GC, Denver RJ. Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides. Gen Comp Endocrinol 2006;146:9-18.
5. Chalmers DT, Lovenberg TW, Gridoriadis DE, Behan DP, De Souza EB. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci 1996;17:166-172.
6. Contarino A, Gold LH. Targeted mutations of the corticotropin-releasing factory system effects on physiology and behavior. Neuropeptides 2002;36:103-116.
7. De Souza EB. Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology 1995;20:789-819.
8. De Wys WD. Management of cancer cachexia. Semin Oncol 1985;12:452-460.
9. Dieterich KD, Lehnert H, De Souza EB. Corticotropin releasing factor receptors: an overview. Exp Clin Endocrinol Diabetes 1997;10:65-82.
10. Donati MB, Mussoni L, Poggi A, De Gaetano G, Garattini S. Growth and metastases of the Lewis lung carcinoma in mice defibrinated with batroxobin. Eur J Cancer 1978;14:343-347.
11. Friedberg M, Zoumakis E, Hiroi N, Bader T, Chrousos GP, Hochberg Z. Modulation of 11 α-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab 2003;88: 385-393.
12. Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G, et al. CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 2002;143:807-813.
13. Harvey KB, Bothe A, Blackburn GL. Nutritional assessment and patient outcome during oncological therapy. Cancer 1979;43:2065-2069.
14. Hashimoto K, Makino S, Asaba K, Nishiyama M. Physiological roles of the corticotropin-releasing hormone receptor type 2. Endocr J 2001;48:1-9.
15. Heldwein KA, Duncan JE, Stenzel P, Rittenberg MB, Stenzel-Poore MP. Endotoxin regulates corticotropin releasing hormone receptor 2 in heart and skeletal muscle. Mol Cell Endocrinol 1997;131:167-172.
16. Henry N, Van Lamsweerde AL, Vaes G. Collagen degradation by metastatic variations of Lewis lung carcinoma: cooperation between tumor cells and macrophages. Cancer Res 1983;43: 5321-5327.
17. Hinkle RT, Donnelly E, Cody D, Bauer MB, Isfort RJ. Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function. Endocrinology 2003;144:4939-4946.
18. Hinkle RT, Donnelly E, Cody DB, Samuelsson S, Lange JS, Bauer MB, et al. Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions. Am J Physiol Endocrinol Metab 2003;285:E889-E898.
19. Keller PA, Bowman M, Dang KH, Garner J, Leach SP, Smith R, et al. Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity. J Med Chem 1999;42:2351-2357.
20. Kishimoto T, Pearse RN, Lin CR, Rosenfeld MG. A sauvagine/corticotropin- releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci USA 1995;92:1108-1112.
21. Koob GF, Heinrichs SC. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 1999;848:141-152.
22. Lippman MM, Laster WR, Abbot BJ, Venditti J, Baratta M. Antitumor activity of macromomycin-B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma. Cancer Res 1975;35:939-945.
23. Llovera M, García-Martínez C, López-Soriano J, Agell N, López-Soriano FJ, Garcia I, et al. Protein turnover in skeletal muscle of tumor-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett 1998;130:19-27.
24. Lovenberg TW, Chalmers DT, Liu C, De Souza EB. CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995;136:4139-4142.
25. Martínez V, Wang L, Rivier JE, Vale W, Tache Y. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther 2002;301:611-617.
26. Mazur AW, Wang F, Tscheiner M, Donnelly E, Isfort RJ. Sauvagine analogs selective for corticotrophin releasing factor 2 receptor: effects of substitutions at positions 35 and 39 on CRFR selectivity. Peptides 2005;26:887-891.
27. McCarthy JR, Heinrichs SC, Grigoriadis DE. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr Pharm Des 1999;5:289-315.
28. Nixon DW, Heymsfield SB, Kutner MM, Ansley J, Lawson DH. Protein-caloric undernutrition in hospitalized cancer patients. Am J Med 1980;68:491-497.
29. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991;43:425-473.
30. Radulovic J, Ruhmann A, Liepold T, Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 1999;19:5016-5025.
31. Reubi JC, Waser B, Vale W, Rivier J. Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 2003;88:3312-3320.
32. Russell ST, Tisdale MJ. The role of glucocorticoids in the induction of zinc-alpha2-glycoprotein expression in adipose tissue in cancer cachexia. Br J Cancer 2005;92:876-881.
33. Samuelsson S, Lange JS, Hinkle RT, Tarnopolsky M, Isfort RJ. Corticotropin-releasing factor 2 receptor localization in skeletal muscle. J Histochem Cytochem 2004;52:967-977.
34. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
35. Seres J, Bornstein SR, Seres P, Willenberg HS, Schulte KM, Scherbaum WA, et al. Corticotropin-releasing hormone system in human adipose tissue. J Clin Endocrinol Metab 2004; 89:965-970.
36. Tjuvajev J, Kolesnikov Y, Joshi R, Sherinski J, Koutcher L, Zhou Y, et al. Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In Vivo 1998;12:1-10.
37. Warren S. The inmediate cause of death in cancer. Am J Med Sci 1932;184:610-613.